# To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions

> **NCT00881127** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 40 (actual)

## Conditions studied

- Allergies

## Interventions

- **DRUG:** Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)
- **DRUG:** Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)

## Key facts

- **NCT ID:** NCT00881127
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2005-07
- **Final completion:** 2005-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00881127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00881127, "To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00881127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*